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Staphylococcus aureus is one of the most important 
human pathogens and meticillin-resistant S. aureus 
(MRSA) presents a major cause of healthcare- and 
community-acquired infections. This study investi-
gated the spatial and temporal changes of S. aureus 
causing bacteraemia in Europe over a five-year interval 
and explored the possibility of integrating pathogen-
based typing data with epidemiological and clinical 
information at a European level. Between January 2011 
and July 2011, 350 laboratories serving 453 hospitals 
in 25 countries collected 3,753 isolates (meticillin-
sensitive S. aureus (MSSA) and MRSA) from patients 
with S. aureus bloodstream infections. All isolates 
were sent to the national staphylococcal reference 
laboratories and characterised by quality-controlled 
spa typing.  Data were uploaded to an interactive web-
based mapping tool. A wide geographical distribu-
tion of spa types was found, with some prevalent in 
all European countries. MSSA was more diverse than 
MRSA. MRSA differed considerably between countries 
with major international clones expanding or receding 
when compared to a 2006 survey. We provide evidence 
that a network approach of decentralised typing and 
visualisation of aggregated data using an interactive 
mapping tool can provide important information on 
the dynamics of S. aureus populations such as early 
signalling of emerging strains, cross-border spread 
and importation by travel.  
Introduction 
Staphylococcus aureus is one of the major causes of 
bacterial infection in humans [1]. Infections occur in the 
community or in healthcare settings, predominantly 
following acquisition from mainly human sources. In 
Europe, meticillin-resistant S. aureus (MRSA) are pre-
dominantly acquired in healthcare settings and rep-
resent a major challenge to the control of antibiotic 
resistance in hospitals. MRSA has therefore become 
the currency with which the success of infection con-
trol initiatives is measured at health systems level [2]. 
S. aureus can also acquire particular virulence traits 
and has been responsible for major outbreaks of toxin-
mediated disease in the community [3]. At the same 
time, S. aureus evolves gradually by successive acqui-
sition of syntenic changes of largely unaltered core 
genomes. It is therefore possible to describe transmis-
sion and the consecutive spread of bacteria by genetic 
characterisation of highly polymorphic sites within 
the core genes of all isolates [4]. The importance of 
S. aureus as a human pathogen, i.e. its potential to 
cause large-scale outbreaks in healthcare settings 
and in the community, and its predominantly clonal 
population structure, calls for a monitoring tool that 
scans the distribution and spread of clones of particu-
lar public health importance over larger temporal and 
spatial intervals through repeated surveys. Such a tool 
is suited to inform public health and infection control 
personnel of impeding health threats.
We therefore continued with a Europe-wide initiative to 
explore and define any dynamic changes in the distri-
bution and spread of clones of S. aureus in European 
hospitals five years after an initial survey was carried 
out in 2006 [5]. We also addressed a request from the 
European Centre for Disease Prevention and Control 
(ECDC) to explore the usefulness of integration of 
molecular typing data with epidemiological and clini-
cal data at a European level.
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Methods
spa typing
Molecular typing for epidemiological purposes utilises 
highly discriminatory genetic markers that character-
ise human pathogens allowing the identification of 
isolates that are distinct versus those that are closely 
related due to recent common ancestry. The spa locus 
of S. aureus codes for Protein A, a species-specific 
gene product known for its IgG binding capacity. This 
locus is highly polymorphic due to an internal variable 
region of short tandem repeats which vary not only in 
number but also due to nucleotide substitutions within 
individual repeat units [6]. DNA sequences of the spa 
gene therefore provide portable and biologically mean-
ingful molecular typing data that have demonstrated 
their utility for macro- and micro-epidemiological pur-
poses from surveillance through to outbreak investiga-
tions at various geographical levels [7,8].
Capacity building
During annually repeated workshops organised for 
technical personnel from European Staphylococcal 
Reference Laboratories (SRL), participants receive 
hands-on training in spa typing and data analysis 
according to a standard protocol using a purpose-
designed software tool StaphType (Ridom GmbH, 
Würzburg, Germany) [8]. Proficiency testing was car-
ried out by mailing each SRL five well-characterised 
S. aureus isolates and five sequence chromatograms 
(trace files) of known spa types as described previously 
[9,10]. All laboratories participating in the structured 
survey described here fulfilled quantifiable quality cri-
teria which consisted of an unambiguous base-calling 
for all sequenced nucleotides for both forward and 
reverse sequencing runs of the test panel.
Structured survey
A protocol was agreed by all participating SRLs in 
June 2010. Using the same network of sentinel labo-
ratories, this by and large followed the sampling 
frame deployed of the first structured survey carried 
out in 2006 [5]. Briefly, European SRLs were asked to 
approach sentinel hospital laboratories which already 
participated in the previous survey and which provide 
microbiological diagnostic services for a geo-demo-
graphically representative sample for their national 
patient population. Between January and July 2011, 
these laboratories were asked to submit the first five 
consecutive MSSA and MRSA isolates from individual 
patients with blood stream infection, from each hos-
pital the laboratories served. If, due to low incidence, 
five MRSA isolates could not be obtained within these 
six months, laboratories were entitled to make up their 
quota of 10 isolates by submitting additional MSSA 
isolates. For small countries with only one laboratory, 
such as Cyprus and Malta, more than 10 samples were 
accepted within this sampling period. Isolates were 
dispatched by the participating laboratories to the 
SRLs and, whenever possible, accompanied by addi-
tional information, including sample number, date of 
isolation, demographic details (such as age and sex), 
epidemiological context (hospital-acquired if disease 
onset was more than 48 hours after admission, or 
community-onset for other cases), antibiotic resist-
ance to isoxazolylpenicillin (i.e. oxacillin) or cefoxitin. 
SRLs confirmed MRSA by mecA PCR or determination of 
minimum inhibitory concentration for oxacillin together 
with PBP2a agglutination. Discrepancies between gen-
otype or agglutination assay and susceptibility test 
were scored as inconclusive phenotypes. Additional 
information could be uploaded to the database and 
web application if available. This consisted of all-cause 
mortality 14 days after isolation of the initial blood-
stream isolate. All SRLs preserved the isolates in strain 
collections and performed spa typing according to the 
standard protocol, uploaded the sequence information 
and made this available by synchronisation with the 
central Ridom SpaServer (www.spaserver.ridom.de) 
curated by SeqNet.org at the University Medical Center 
Groningen, the Netherlands [10,11]. Currently there 
are more than 13,000 spa-types and 630 repeat units 
stored on the SpaServer.
Epidemiological and typing data were communicated in 
parallel to a central purpose-designed structured query 
language (SQL) database at the Netherlands’ National 
Institute for Public Health and the Environment (RIVM). 
For each local laboratory, SRLs also provided the postal 
address and decimal Cartesian coordinates for auto-
matic geolocation. All data were anonymised and col-
lected in accordance with the European Parliament and 
Council decision for the epidemiological surveillance 
and control of communicable disease in the European 
community [12,13]. Ethical approval and informed con-
sent were thus not required.
Data analysis and geographical illustration
All data were inspected for inconsistencies and ana-
lysed on a country-by-country basis and returned to 
SRLs for feedback, clarification of inconsistencies and 
final approval in July 2012. After final approval, data 
were analysed using Stata version 11.0 (College Station, 
Texas, USA) using Pearson chi-squared test and 
Fischer’s exact test for proportions and Student t-test 
for continuous variables. Quantitative differences with 
the 2006 survey were reported as results. The index of 
diversity (ID) is an unbiased measure of the probability 
of drawing two different spa types given the distribu-
tion of spa types in the sample. The 95% confidence 
intervals (CIs) were calculated as described previously 
[14]. Multilocus sequence typing (MLST) sequence 
types were extrapolated from the spa type as per the 
Ridom SpaServer. Cartesian coordinates were used 
for geolocation and plotting on Google Maps using 
the geocoding facility at www.spatialepidemiology.
net [15]. The web application SRL-Maps (http://www.
spatialepidemiology.net/SRL-Maps2) was developed to 
interrogate the data based on mapping of laboratory 
locations.
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Results
Summary statistics
Between January and July 2011, laboratories from 25 
European countries participated in this survey. These 
included 22 European Union (EU) Member States 
(Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, 
Finland, France, Germany, Greece, Hungary, Ireland, 
Italy, Latvia, Malta, Netherlands, Poland, Portugal, 
Romania, Slovenia, Spain, Sweden, United Kingdom), 
two European Economic Area (EEA) countries (Iceland 
and Norway) and Switzerland. For the United Kingdom, 
Scotland participated on its own behalf, whereas 
England, Northern Ireland and Wales all referred 
isolates to the same reference centre in England. 
Two countries (Cyprus and Malta) took the deliber-
ate decision to carry out the necessary investigations 
in partner (twinning) laboratories, as the sample vol-
ume would not otherwise have justified the necessary 
investment for sequencing equipment. Since they were 
also allowed to submit a larger quota, they submitted 
34 and 20 isolates respectively.
Altogether, 350 laboratories (Figure 1) serving 453 hos-
pitals submitted data for 3,753 S. aureus isolates from 
patients with bloodstream infections, isolated dur-
ing the six-month investigation period. Table 1 gives 
a summary overview of the number of participating 
Figure 1
Geographical location of laboratories that contributed to survey of meticillin-sensitive Staphylococcus aureus and meticillin-
resistant S. aureus isolates, 2011 
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laboratories and hospitals, isolates and spa types sub-
mitted by country. The combined collection consisted 
of 2,621 (69%) MSSA and 1,130 (31%) MRSA. Two iso-
lates had an inconclusive resistance phenotype. One 
was spa-type t127 and the other spa non-typable.
A total of 861 different spa types were discerned, of 
which 720 were MSSA and 228 MRSA. Of these, 87 spa 
types were shared between MSSA and MRSA. When 
compared with results obtained during 2006, the spa 
type per isolate ratio remained at 0.23, indicating a 
similar sample diversity in both surveys. There were 51 
isolates (out of a total of 3,753; 1.4%) which were spa 
non-typable. Typability of isolates ranged from 93.3% 
to 100% depending on the country.
Bloodstream infections with S. aureus occurred at an 
older age (median 68 years, Table 2) and predominantly 
in men, which is in accordance with previous findings 
[5,16]. The proportion of isolates from men was higher 
among MRSA than MSSA bloodstream infections 
(p=0.03). The median age at infection with MRSA was 
three years older than for infection with with MSSA. 
Compared with 2006 data, the age distribution for both 
MSSA and MRSA in 2011 had shifted slightly to older 
age groups (p<0.001).
In 2011, data on all-cause mortality 14 days after index 
blood culture were available for 65.5% of all cases. 
Overall all-cause mortality was 19.4% (477/2,458). 
There was a difference between MRSA and MSSA in 
Table 1
Summary overview of participating laboratories, hospitals, number of invasive isolates of meticillin-sensitive Staphylococcus 
aureus and meticillin-resistant S. aureus and spa types by country, 25 European countries, 2011 
Country Number of laboratories
Number of 
hospitals
Number of
 isolates MSSA MRSAa
Number of 
spa types 
MSSA
Number of 
spa types 
MRSA
Number not 
typable
Percentage 
non-typable
Belgium 17 17 133 76 57 53 25 3 2.2
Bulgaria 11 11 46 33 13 25 8 0 0.0
Cyprus 1 1 34 20 14 17 10 1 2.9
Czech Republic 20 20 144 95 49 63 9 0 0.0
Denmark 16 58 288 276 10 150 7 2 0.7
Finland 17 43 173 163 10 89 5 2 1.2
France 34 34 286 166 120 98 31 3 1.0
Germany 10 26 161 100 61 62 22 0 0.0
Greece 1 13 85 47 38 33 15 0 0
Hungary 13 13 125 74 51 39 13 1 0.8
Iceland 1 1 9 7 2 6 2 0 0.0
Ireland 21 27 193 117 76 68 21 13 6.7
Italy 23 23 200 103 97 61 36 0 0.0
Latvia 8 8 36 33 3 17 2 1 2.8
Malta 1 1 20 10 10 10 7 0 0
Netherlands 2 16 138 130 8 77 5 7 5.1
Norway 22 n.d. 84 80 4 61 3 0 0.0
Poland 49 52 391 312 79 136 25 0 0.0
Portugal 1 19 195 99 96 52 23 0 0.0
Romania 5 5 37 15 22 13 7 0 0.0
Slovenia 10 13 164 142 22 40 3 9 5.5
Spain 1 30 129 35 94 30 27 0 0.0
Sweden 23 n.d. 225 215 10 114 10 1 0.4
Switzerland 6 6 60 46 14 39 9 1 1.7
United Kingdom: 
England, Northern 
Ireland and Wales
16 16 164 108 56 63 25 7 4.3
United Kingdom: 
Scotland 21 n.d. 233 119 114 69 35 0 0.0
Total 350 453 3,753 2,621 1,130 720 228 51 1.4
MSSA: meticillin-sensitive Staphylococcus aureus; MRSA: meticillin-resistant S. aureus; N.d.: not determined.
a  Note that the number of MRSA does not reflect a prevalence or occurrence in particular countries as the protocol asked for submission of 
the first five isolates of each phenotype.  
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terms of all-cause mortality: 17.1% of patients with 
MSSA infections died, compared with 24.4% of patients 
with MRSA (p<0.001). This difference was also identi-
fied in 2006 and is explained by various confounders 
that put MRSA patients at a higher risk of dying than 
those with MSSA infections [17]. Overall, there were 
more patient deaths in 2011 compared with the 2006 
survey (16%, p=0.004). Although observed for both 
MSSA and MRSA infections, this trend was only sig-
nificant for MRSA infection (p=0.004). Whether this 
difference indicates an evolution towards more viru-
lence or changes in host factors such as the increase in 
age is something that cannot be determined from this 
dataset.
Disease onset occurred in the community for 56% of 
MSSA and 33.4% of MRSA infections, indicating that 
MRSA remains predominantly hospital-acquired. But 
there was a significant increase in the proportion of 
cases with community onset compared with the pre-
vious survey (in 2006 48.4% of MSSA infections had 
community onset, p<0.001; for MRSA in the same 
year it was 28.3%, p=0.02). A comparison of the most 
prevalent spa types among hospital-acquired MRSA 
(HA-MRSA) and community-onset isolates (CO-MRSA) 
revealed little difference (not shown). In the 2011 sam-
ple, the five top ranking spa types comprised 52% and 
45% of all HA-MRSA and CO-MRSA respectively.
The high overall diversity (ID=0.985) is indicative of the 
good discriminatory ability of spa typing but, as with 
the 2006 sample, there has been a significant differ-
ence between MSSA and MRSA as a result of the oligo-
clonal nature of MRSA spreading through European 
countries.
Overall distribution of spa types
For MSSA, the top 20 ranking spa types included 
43.2% of all MSSA isolates (Table 3). Importantly, there 
was very little difference among the first 11 ranking 
spa types between the 2011 and 2006 datasets. Only 
changes in rank order were observed. Ranks 12 to 20 
contained four new spa types in 2011 (Table 3).
Table 3
The 20 most frequent spa types and multilocus sequence typing types among meticillin-sensitive Staphylococcus aureus and 
meticillin-resistant S. aureus isolates collected in 25 European countries in 2011
MSSA MRSA
 Rank spa type
Multilocus 
sequence 
typea
Frequency % Cumulative% Rank spa type
Multilocus 
sequence 
typea
Frequency % Cumulative% 
1 t091 ST7 138 5.3 5.3 1 t032 ST22 202 17.9 17.9
2 t084 ST15 124 4.7 10.0 2 t003 ST225 99 8.8 26.6
3 t002 ST5 121 4.6 14.6 3 t008 ST8 95 8.4 35.0
4 t015 ST45 98 3.7 18.4 4 t002 ST5 87 7.7 42.7
5 t008 ST8 97 3.7 22.1 5 t067 ST125 50 4.4 47.2
6 t012 ST30 90 3.4 25.5 6 t041 ST228 24 2.1 49.3
7 t127 ST1 83 3.2 28.7 7 t777 ST5 21 1.9 51.2
8 t021 ST30 50 1.9 30.6 8 t018 ST36 20 1.8 52.9
9 t065 ST45 38 1.4 32.1 9 t022 ST22 20 1.8 54.7
10 t026 ST45 34 1.3 33.4 10 t037 ST239 19 1.7 56.4
11 t005 ST22 33 1.3 34.6 11 t127 ST1 18 1.6 58.0
12 t230 ST45 32 1.2 35.9 12 t747 ST22 17 1.5 59.5
13 t216 ST59 28 1.1 36.9 13 t044 ST80 15 1.3 60.8
14 t056 ST101 27 1.0 38.0 14 t2357 ST22 15 1.3 62.1
15 t148 ST72 25 1.0 38.9 15 t024 ST8 14 1.2 63.4
16 t024 ST8 23 0.9 39.8 16 t740 ST45 12 1.1 64.4
17 t346 ST15 23 0.9 40.7 17 t515 ST22 12 1.1 65.5
18 t571 ST398 23 0.9 41.5 18 t6057 ST22 11 1.0 66.5
19 t701 ST8 23 0.9 42.4 19 t030 ST239 9 0.8 67.3
20 t189 ST188 21 0.8 43.2 20 t014 ST225 9 0.8 68.1
Other - - 1,489 56.8 100.0 other -    - 361 31.9 100.0
Total 2,621 100 Total 1,130 100
MLST: multilocus sequence typing; MSSA: meticillin-sensitive Staphylococcus aureus; MRSA: meticillin-resistant S. aureus; %: percentage.
a Predicted from spa typing data.
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For MRSA, the top 20 ranking MRSA spa types contained 
68.1% of all MRSA isolates (73.4% in 2006). There were 
no differences in the top six spa types (albeit in relative 
ranking). t032/ST22 now comprises 17.9% of all MRSA 
sampled in 2011 (up from 14.5% in 2006, p=0.036, 
Figure 2, Table 3). Except for t515, all ST22 related spa 
types (t032, t022, t747, t2357, t6057) have significantly 
increased in frequency and this lineage made up 36% 
of the top 20 ranking isolates in 2011, whereas in 2006 
this figure was still lower at 23%. Three spa types have 
significantly decreased compared to the 2006 collec-
tion. t008/ST8, mainly found in France, decreased 
from 12.4% to 8.4% (p=0.003). t041/ST228 decreased 
from 7.4%  in 2006 to 2.1% in 2011 (p<0.001). Finally, 
international clone t030/ST239 decreased from 2.1% to 
0.8% (p=0.013).
Discussion
This survey represents a repetition of a previous study 
carried out in 2006 and was designed to investigate (i) 
the temporal and spatial changes of S. aureus clones of 
particular public health importance in Europe, and (ii) 
the feasibility and utility of integrating molecular typ-
ing data with epidemiological and clinical information 
at a European level.
We previously demonstrated the feasibility of creating 
a collaborative consortium of SRLs across Europe and 
alignment of S. aureus typing methodology in addition 
to harmonising processes and data format at European 
level [5]. The continuation of this effort has shown that 
collaboration between countries can be maintained 
over extended intervals and provide added value to 
the understanding of the dynamic spread of S. aureus 
while quality, consistency of molecular typing and 
communication improves.
The results described here are testimony to the useful-
ness of structured surveys to generate information for 
public health action in a timely and economic fashion. 
Repeating surveys through previously created networks 
of sentinel hospital laboratories allows for consist-
ent observations about the changing epidemiology of 
infections caused by bacterial clones of particular pub-
lic health importance. In case of S. aureus, these clones 
are responsible for community and hospital-acquired 
infections, and they are often resistant to a range of 
antibiotic compounds and circulate among patients of 
extended hospital referral networks in Europe. They 
typically have a defined geographical distribution and 
show a steady diffusion along hospital patient referral 
lines. Moreover, our results suggest that HA-MRSA is 
filtering into the community at an increasing rate. The 
proportion of community-onset infections caused by 
international HA-MRSA clones has increased over the 
last five years from 28.3% to 33.4%. This difference 
is significant (p<0.001) and relevant as it indicates a 
trend to more export of hospital-associated clones 
Figure 2
Comparison of meticillin-resistant Staphylococcus aureus spa-type frequencies, 2011 and 2006
Brackets over the bars indicate the bars for which p values were calculated.
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into the community, probably as a result of patients’ 
shorter hospital stays.
Among MRSA isolates, a dynamic expansion was dem-
onstrated for several spa types. MRSA isolates with 
spa types belonging to ST22 increased most markedly 
making ST22 the most critically expanding MRSA clone 
in Europe. This lineage (designated EMRSA-15) was 
first described during hospital outbreaks in England. 
It caused a nationwide epidemic of healthcare-associ-
ated infections in the 1990s and is still the most prev-
alent HA-MRSA in the UK [18]. This clone has spread 
from the UK and Ireland and has become abundant in 
Germany, Hungary, Portugal and Northern Italy. MRSA 
belonging to spa type t018/ST36 has attained a foot-
hold in Poland and t067/ST125, abundant in Spain dur-
ing the 2006 survey [19], has been causing an outbreak 
in hospitals in a single health district in Finland in 2011 
[20]. Among MSSA, spa type t571/ST398 appears to 
be spreading in France and Belgium [21]. Our observa-
tions indicate that infections with this clone are more 
frequent among younger men and may be associated 
with higher mortality. Its MRSA counterpart has been 
described as an ancestral human variant [22] of the 
livestock-associated MRSA clone ST398, which caused 
outbreaks of community-acquired infections in north-
ern Manhattan that were linked to immigrants from 
the Dominican Republic [23]. Conversely, a reduction 
of international clone ST239 consisting of the spa 
types t030 and t037 and t041/ST228 was observed. 
It appears that the decline of ST239 is genuine as it 
mainly occurred in Poland, whereas the reduction of 
t041/ST228 can be explained by the fact that Austria 
and Croatia did not participate in the 2011 survey. Both 
countries contributed a high proportion of this type to 
the 2006 dataset. This highlights the importance of 
consistent participation in these types of pathogen-
specific surveillance initiatives and the vulnerability of 
networks that depend on the goodwill and enthusiasm 
of participants.
Limitations of this study that deserve to be addressed 
include a deliberate decision that was taken by the 
SRLs to provide only isolates from bloodstream infec-
tions. This slight deviation from the sampling frame 
of the previous survey may have skewed the spa type 
distribution slightly. Moreover, the fixed number of iso-
lates that were collected from each participating centre 
was due to the trade-off between the desire to make 
the workload of SRLs predictable and manageable and 
the inability to precisely determine incidence and the 
absolute increase or decrease of spa types. Thus, find-
ings generated through these types of structured sur-
veys must be put into context of surveillance data from 
other European-wide initiatives such as the European 
Respiratory Society’s (ERS-net) and/or the Healthcare-
Associated Infections Surveillance Network (HAI-net). 
The nature of structured surveys does not allow for 
early warning and response as it merely provides a 
rather static population snapshot of the spa types, 
i.e. clones that were extant and caused bloodstream 
infections at the time of sampling. The value of these 
snapshots should not be underestimated, however, as 
they provide an unbiased view which can be used to 
identify clones of public health importance and their 
geographic abundance and can inform ad hoc epidemi-
ological investigations about the dignity and geograph-
ical origin of organisms isolated during outbreaks.
The exchange of typing results using an illustrative 
mapping tool such as the spatialepidemiology.net 
website’s SRL-maps provides the means to determine 
the reach and expansion of clones with proven suc-
cess simultaneously for different countries. Initiatives 
such as these could lead to an improved and sustain-
able effort to control and eradicate emerging high-risk 
clones at the level of healthcare institutions once inter-
national agencies secure the sustainability for these 
repeated efforts.
A consistent integration of typing data with pre-exist-
ing epidemiological and or clinical data collected 
through other European surveillance initiatives (such 
as the European Antimicrobial Resistance Surveillance 
Network (EARS-net), European Surveillance of 
Antimicrobial Consumption Network (ESAC-net) or HAI-
net) will,  depend on the successful implementation of 
further alignment of sampling methodology, diagnos-
tic procedures and of the regulatory framework across 
Europe. It would require a systematic and internation-
ally accepted identification-code for hospitals and 
diagnostic laboratories, as well as for bacterial iso-
lates, which are reported through different surveillance 
initiatives and for patients from whom these organ-
isms were originally recovered. This would require 
novel regulatory approaches on the part of European 
national governments. Moreover, data protection 
and confidentiality issues would need to be resolved 
before such regulations could be enacted. The alter-
native would be a fully decentralised approach. This 
would require additional efforts from hospitals and 
laboratories to provide pertinent epidemiological and 
clinical information in addition to molecular typing and 
antibiotic susceptibility data and to report this bun-
dled information while maintaining full confidentiality. 
However, as such efforts require a considerable degree 
of reorganisation they may seem unrealistic under the 
current climate of austerity. During the deliberations 
with the representatives of the SRLs in our study , 
the possibility of collecting more accurate data about 
source patients (epidemiology and clinical outcome) 
was appraised. The prevailing consensus was that this 
would be unrealistic given the scarcity of information 
provided to diagnostic laboratories by clinicians on the 
request forms and the inability of laboratories to fund 
these additional enquiries from their own budgets. It is 
important to note that these concerns were not raised 
by single members of the SRL working group, but 
appear to represent a common view. 
In conclusion, collaborative typing initiatives are able 
to identify the continental spread of high-risk clones 
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across national boundaries and can indicate to health-
care providers the emergence of threats caused by 
successful and antibiotic-resistant bacteria. The geo-
graphic diffusion of antibiotic-susceptible and resist-
ant clones of S. aureus can be made visible with the 
help of intuitive information tools such as interactive 
websites. This can improve the coherence of individual 
laboratory results and contribute to a better under-
standing of the population dynamic of these important 
pathogens. A simple integration of typing data with 
data from other existing surveillance efforts is, how-
ever, currently constrained by regulatory hurdles and 
legitimate concerns about patient data protection. 
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